VX-561

DRUG5 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Cystic Fibrosis

Phase 1

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

CompletedNCT03227471

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2017-01-23End: 2018-03-27Updated: 2022-01-18

Phase 2

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

TerminatedNCT02971839

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2016-12-31End: 2017-08-31Updated: 2020-08-26

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

CompletedNCT03224351

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2017-08-08End: 2018-02-28Updated: 2021-04-22

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

CompletedNCT03912233

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2019-04-30End: 2019-12-10Updated: 2023-04-20

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

CompletedNCT03911713

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2019-04-17End: 2020-08-20Updated: 2022-01-25

Related Papers

Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.

2023-02-2342 citations

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

New England Journal of Medicine2018-10-18707 citations

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

New England Journal of Medicine2018-10-18320 citations